President Donald Trump’s choice to lead the Food and Drug Administration has unraveled after Heidi Overton drew mounting resistance from Democrats, Republicans and even members of Health Secretary Robert F. Kennedy Jr.’s MAHA movement.
The White House decided Tuesday to drop Overton’s nomination after determining she lacked sufficient support in Congress, Axios reported, citing a senior administration official.
“FDA nominee Heidi Overton lacks the support on the Hill to move forward with her confirmation,” the official told Axios.
Overton, a physician who serves as deputy director of the White House Domestic Policy Council, was nominated in August but quickly became a controversial choice to oversee the agency.
Her nomination drew criticism from supporters of Kennedy’s Make America Healthy Again movement, some of whom accused her of siding with agricultural and health industry interests at the expense of Kennedy’s agenda.
“Antiabortion forces also questioned her commitment to tightening rules for prescribing the abortion pill mifepristone,” Axios reported.
But the opposition extended beyond the administration’s conservative base.
Sen. Bill Cassidy (R-LA), chairman of the Senate Health, Education, Labor and Pensions Committee, previously expressed “strong concerns” about Overton’s involvement in efforts to overhaul childhood vaccine recommendations, calling her role “almost disqualifying.”
Democrats also opposed her nomination, leaving her confirmation prospects increasingly uncertain ahead of a committee vote scheduled for Wednesday.
The senior administration official told the outlet that the White House wanted to “go in a new direction at FDA” while continuing to support Kennedy’s health agenda.
“The decision means the Trump administration will have to find a new candidate to lead the FDA,” Axios said.
The agency has operated under acting Commissioner Kyle Diamantas since Marty Makary resigned in May.